{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "9473131", "DateCompleted": {"Year": "1998", "Month": "03", "Day": "26"}, "DateRevised": {"Year": "2019", "Month": "06", "Day": "24"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0014-2999", "JournalIssue": {"Volume": "339", "Issue": "2-3", "PubDate": {"Year": "1997", "Month": "Nov", "Day": "27"}}, "Title": "European journal of pharmacology", "ISOAbbreviation": "Eur J Pharmacol"}, "ArticleTitle": "Cardiac hypertrophy determines digitalis action on intracellular Ca2+ in human myocardium.", "Pagination": {"StartPage": "161", "EndPage": "164", "MedlinePgn": "161-4"}, "Abstract": {"AbstractText": ["Ventricular hypertrophy alters transporters associated with digitalis action, but the outcome of digitalis treatment on intracellular cations in the hypertrophied human myocardium remains unknown. Using double-barreled Ca2+-selective microelectrodes, we simultaneously measured Ca2+ activity and membrane potential in myocardial samples from patients without and with ventricular hypertrophy, prior to and following exposure to strophanthidin, a prototype digitalis. We found that ventricular hypertrophy is associated with greater strophanthidin-induced increase in diastolic Ca2+ levels compared to that observed in the absence of hypertrophy. Furthermore, in hypertrophied myocardium the magnitude of the increase in Ca2+ induced by strophanthidin was inversely related to increase in myocardial mass. Thus, the extent of ventricular hypertrophy determines digitalis action on intracellular Ca2+ within the human myocardium."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela."}], "LastName": "Lopez", "ForeName": "J R", "Initials": "JR"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Linares", "ForeName": "N", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Brady", "ForeName": "P A", "Initials": "PA"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Terzic", "ForeName": "A", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Eur J Pharmacol", "NlmUniqueID": "1254354", "ISSNLinking": "0014-2999"}, "ChemicalList": [{"RegistryNumber": "66-28-4", "NameOfSubstance": "Strophanthidin"}, {"RegistryNumber": "SY7Q814VUP", "NameOfSubstance": "Calcium"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["metabolism"], "DescriptorName": "Calcium"}, {"QualifierName": [], "DescriptorName": "Digitalis"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Hypertrophy, Left Ventricular"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["metabolism"], "DescriptorName": "Myocardium"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Plants, Toxic"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Strophanthidin"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1998", "Month": "2", "Day": "24"}, {"Year": "1998", "Month": "2", "Day": "24", "Hour": "0", "Minute": "1"}, {"Year": "1998", "Month": "2", "Day": "24", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["9473131", "10.1016/s0014-2999(97)01398-8", "S0014-2999(97)01398-8"]}}]}